Skye initiated at overweight at Evercore on obesity asset nimacimab

[Wall street.]
bodrumsurf

* Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE [https://seekingalpha.com/symbol/SKYE]) due to its development of the CB1 inhibitor nimacimab for obesity.
* The firm has a $10 price target (~206% upside based on Thursday's close).
* Analyst Michael DiFiore believes that as a CB1 inhibitor, nimacimab would differentiate itself from the GLP-1s from Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) that are dominating the market.
* He noted that the candidate could fill gaps in obesity care in several ways: as a GLP-1 off-ramp/maintenance option; as a combo therapy in severe obesity; and as a non-incretin monotherapy for some patients.
* DiFiore added that the newest generation of CB1 inhibitors appears to avoid the central nervous issues that plagued earlier generations.
* Looking ahead, he sees the next major catalyst for nimacimab coming in late Q3 or early Q4 with phase 2a data.

MORE ON SKYE BIOSCIENCE

* Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4810721-skye-bioscience-inc-skye-q2-2025-earnings-call-transcript]
* Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing [https://seekingalpha.com/article/4799779-skye-bioscience-partners-with-arecor-potentially-enhanced-nimacimab-dosing]
* Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform [https://seekingalpha.com/news/4482170-skye-bioscience-signals-late-q3-early-q4-top-line-phase-iia-results-as-nimacimab-advances]
* Skye Bioscience GAAP EPS of -$0.44 misses by $0.13 [https://seekingalpha.com/news/4481749-skye-bioscience-gaap-eps-of-0_44-misses-by-0_13]
* Seeking Alpha’s Quant Rating on Skye Bioscience [https://seekingalpha.com/symbol/SKYE/ratings/quant-ratings]